In-depth guides
Focused explainers place terminology, study design, safety questions, and legal context beside one another. They are built to help readers identify what a source does—and does not—show.
Independent information services
Services
Guides, comparisons, and research summaries for adults asking careful questions about psilocybin and ibogaine—without turning uncertainty into a promise.
A steadier way to compare.
Psilocybin and ibogaine are often discussed together, but their research histories, risk profiles, legal settings, and reported experiences are not interchangeable. Our central comparison of psilocybin and ibogaine begins with those meaningful differences rather than a single answer for every person.
Steady Lantern 69 is an independent resource for comparing emerging psychedelic therapies. The work is guided by our approach to evidence awareness and risk transparency: plain language, respectful nuance, and clear limits on what information can establish.
What we offer
Information tools for a complex question.
Side-by-side comparisons
Comparison pages separate broad similarities from consequential differences. For instance, the ibogaine MMA discussion can be considered as one distinct context, not as proof that either substance is appropriate for anyone.
Research summaries
We translate study language carefully and leave uncertainty visible. The National Center for Complementary and Integrative Health overview of psychedelic and dissociative drugs likewise notes that research and safety questions remain active areas of inquiry.
Glossary and FAQ collections
Short definitions and recurring questions support more deliberate reading. They are information services, not screening, diagnosis, treatment planning, or a substitute for professional medical or legal guidance.
Guided explanation
Keep the important distinctions in view.
Names can make two substances sound more alike than they are. Psilocybin is a naturally occurring psychedelic compound, while ibogaine is an alkaloid associated with the iboga plant; their meanings in research and public discussion are shaped by different histories. A basic reference point is the overview of psilocybin, but a starting definition is not a personal safety assessment.
Questions about cost, location, marketing, or access should not eclipse questions about evidence and risk. A page such as ibogaine treatment costs in Mexico may address a practical concern, while the broader question still requires careful attention to claims, oversight, and legal context.
“A grounded comparison does not choose for the reader. It makes room for the facts, limits, and questions that deserve to stay visible.”
Decision framework
Questions worth carrying forward.
What is being claimed?
Our framework distinguishes a personal account, a marketing statement, a preliminary finding, and a supported conclusion. The relationship between ibogaine and martial arts is one example of a topic that benefits from keeping context separate from evidence.
What risks are discussed?
Risk transparency means not minimizing uncertainty. Readers exploring ibogaine-related material can compare practical information with sources such as Canadian ibogaine information while remembering that online information cannot evaluate individual circumstances.
Who benefits from the wording?
We encourage readers to notice whether language is educational, promotional, or both. Material about ibogaine stock and market interest may involve commercial questions that are distinct from health and safety questions.
What remains unknown?
A useful summary ends with limits, not certainty. Research involving psychoactive substances is affected by study size, participant selection, setting, law, and the difference between controlled research and real-world claims.
Common questions
Clear answers, without false certainty.
The purpose of these services is to make a difficult subject easier to examine, not to make a health decision on anyone’s behalf.
Do these information services recommend a treatment?
No. Steady Lantern 69 provides comparison tools, guides, and research summaries, not treatment recommendations or medical advice.
Why compare psilocybin and ibogaine separately?
They have different research histories, legal contexts, effects, and risk considerations. A careful comparison helps keep those differences visible.
Can practical access information answer a safety question?
No. Practical details and safety claims are different kinds of information. A resource discussing an ibogaine treatment facility in Mexico may be relevant to access research, but it cannot provide individualized medical guidance.
Why is legal context included?
Access and legality change across jurisdictions and over time. The DEA’s drug scheduling information provides one official U.S. reference point, though it does not replace current local legal advice.
Start with the question
Approach comparison with care.
Return to the overview for a plainspoken foundation in the differences, uncertainties, and risk-aware questions surrounding psilocybin and ibogaine.
Explore the comparison